Shanghai-based medical technology company Novosense has introduced its latest technology, the NOVOSENSE NST1002, which is designed to facilitate accurate continuous glucose monitoring (CGM) in diabetes patients. Glucose monitoring is a critical aspect of diabetes management, and the two main methods currently in use are traditional blood glucose monitoring (BGM) and CGM. While BGM is a well-established method of glucose monitoring, CGM is fast emerging as a preferred method owing to its ability to provide dynamic, comprehensive, and reliable glucose information throughout the day.
CGM involves real-time monitoring of glucose concentrations in subcutaneous tissue fluids using implanted glucose sensors. The sensor is a critical component of the CGM system and determines whether the measurement results of the system are accurate or not. The NST1002 sensor from Novosense is designed to overcome the technical difficulties of CGM and deliver accurate glucose monitoring data.
Also Read:
A sensor comprises an electrode, film layer, sensing layer, and calibration algorithm that determine its performance. The CGM system measures the glucose concentration in interstitial fluid, which has a high correlation with glucose concentration. However, the differences between the two vary and are not constant due to different physiological states and environmental factors, which can cause measurement errors. These problems are solved using the calibration algorithm. The ambient temperature or body surface temperature is a critical variable in the algorithm model that significantly affects the effectiveness of the algorithm model.
The NOVOSENSE NST1002 sensor is a high-precision, low-power temperature sensor that senses changes in ambient temperature or body surface temperature in real-time and adjusts the algorithm accordingly to deliver more accurate glucose monitoring results. The sensor is designed to be close to the skin of the body surface to achieve accurate body surface temperature collection, which provides more effective data. With Novosense’s rich experience in surface temperature acquisition solutions, customers can quickly complete product structure design and material selection.
Also Read:
The interstitial fluid glucose sensor probe is less than 0.4 mm in diameter and can be inserted 5 mm below the skin to ensure accurate sensing of glucose concentration in the interstitial fluid outside the cells. The structure design and installation position of the NST1002 sensor are a critical aspect of CGM products. Novosense’s NST1002 sensor technology tackles the challenges of CGM and provides a solution for accurate glucose monitoring.
The NOVOSENSE NST1002 facilitates accurate glucose monitoring for diabetes patients and has significant implications for diabetes management. Novosense is committed to developing advanced technology to improve patient outcomes and enhance the quality of life for diabetes patients. The NST1002 technology, with its high-precision, low-power temperature sensor, is the latest example of Novosense’s commitment to advancing diabetes management.
Also Read:
The NST1002 sensor technology is expected to have a significant impact on the diabetes market globally, particularly in countries with a high incidence of diabetes. According to the International Diabetes Federation, an estimated 463 million adults were living with diabetes in 2019, and the number is projected to rise to 700 million by 2045. These statistics underscore the need for innovative solutions in diabetes management. Novosense’s NST1002 sensor technology is a significant development in diabetes management that has the potential to benefit millions of diabetes patients worldwide.
In Other News Around the World: